Seven days following the administration of CD44-IR700, the tumour volume ratio relative to day 0 was recorded as 4.3 for the Ctrl group, 2.2 for the CD44-IR700_IV group, and 1.0 for the CD44-IR700_IT group, with statistically significant differences as determined using the Kruskal–Wallis test, followed by Dunn's test adjusted with Bonferroni correction (Fig. 3f). This evidence concerns the gene CD44 and neoplasm.